NCT00441818View on ClinicalTrials.gov

Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

May 31, 2006

Study Completion Date

June 30, 2007

Conditions
Hodgkin's Lymphoma
Interventions
DRUG

TNX-650

Trial Locations (2)

10021

NOT_YET_RECRUITING

Memorial Sloan-Kettering Cancer Center, New York

77030-4009

RECRUITING

MD Anderson Cancer Center - Dept. of Lymphoma and Myeloma, Houston

Sponsors

Lead Sponsor

Tanox
All Listed Sponsors
lead

Tanox

INDUSTRY

NCT00441818 - Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter